Notice 17 Mar 2025 pharmaceuticals, import regulations, dea, controlled substances, fisher clinical services

💊Fisher Clinical Services' Application for Controlled Substance Importation

Fisher Clinical Services, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 14 Mar 2025 regulatory compliance, pharmaceuticals, fda, health, drug approval

💊FDA Withdraws Approval of Abbreviated New Drug Applications

The Food and Drug Administration (FDA or Agency) is withdrawing approval of four abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

Learn More
Notice 14 Mar 2025 healthcare, pharmaceuticals, fda, drug approval, sage therapeutics

💊FDA Withdraws Approval for ZULRESSO (Brexanolone) Solution

The Food and Drug Administration (FDA or Agency) is withdrawing approval of a new drug application (NDA) for ZULRESSO (brexanolone) solution, 100 milligrams (mg)/20 milliliters (mL), held by Sage Therapeutics, Inc., 55 Cambridge Parkway, Cambridge, MA 02142 (Sage). Sage notified the Agency in writing that the drug product was no longer marketed and requested that the approval of the application be withdrawn.

Learn More
Notice 13 Mar 2025 compliance, regulatory, pharmaceuticals, dea, controlled substances, drug manufacturing, patheon

💊Patheon Pharmaceuticals Applies for Controlled Substances Manufacturing Registration

Patheon Pharmaceuticals Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

Learn More
Notice 13 Mar 2025 regulations, pharmaceuticals, manufacturing, controlled substances, drug enforcement, sigma aldrich

⚗️Sigma Aldrich Controlled Substances Application Overview

Sigma Aldrich Research Biochemicals Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

Learn More
Notice 6 Mar 2025 compliance, pharmaceuticals, import regulations, controlled substances, indvior inc, dea

💊Indivior Inc. Seeks Registration for Importing Controlled Substances

Indivior Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 6 Mar 2025 nih, evaluation, funding, pharmaceuticals, grants, research, biotechnology

💰NIH Closed Meetings

The Department of Health and Human Services announces closed meetings by the National Institutes of Health to review grant applications for various scientific study sections. These meetings intend to focus on evaluating proposals that may involve confidential trade secrets and personal information. The meetings will be conducted virtually and are closed to the public.

Learn More
Notice 28 Feb 2025 air quality, pharmaceuticals, emissions regulation, compliance, epa

🏭EPA NESHAP for Pharmaceuticals Production Renewal Notice

The Environmental Protection Agency (EPA) has submitted an information collection request (ICR), NESHAP for Pharmaceuticals Production (EPA ICR Number 1781.10, OMB Control Number 2060-0358) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act. This is a proposed extension of the ICR, which is currently approved through February 28, 2025. Public comments were previously requested via the Federal Register on May 18, 2023 during a 60-day comment period. This notice allows for an additional 30 days for public comments.

Learn More
Notice 28 Feb 2025 antitrust, biotechnology, research and development, business partnerships, pharmaceuticals, regulatory compliance

🚀DOJ Notice on Membership Changes in Rapid Response Partnership Vehicle

The Department of Justice's notice announces changes in the membership of the Rapid Response Partnership Vehicle (RRPV) under the National Cooperative Research and Production Act. New members have been added, while one has withdrawn. The notice emphasizes that no other changes in the group's activities or membership status were made, and future notifications are anticipated.

Learn More
Notice 21 Feb 2025 compliance, pharmaceuticals, foreign-trade zone, new jersey, merck, production authorization

💊Merck Authorized for Production in Foreign-Trade Zone 49

The Foreign-Trade Zones Board has authorized Merck, Sharp & Dohme LLC to conduct production activities for pharmaceutical products within FTZ 49 in Rahway, New Jersey. This decision follows a review process, indicating compliance with federal regulations and allowing for enhanced operational support in the pharmaceutical sector.

Learn More